CollPlant Biotechnologies
CLGN
16 hedge funds and large institutions have $7.39M invested in CollPlant Biotechnologies in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
23% more funds holding
Funds holding: 13 → 16 (+3)
0.62% more ownership
Funds ownership: 12.37% → 12.99% (+0.62%)
3% less capital invested
Capital invested by funds: $7.59M → $7.39M (-$198K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
+$420K |
| 2 |
PA
Pinnacle Associates
New York
|
+$188K |
| 3 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$127K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.1K |
| 5 |
RWMG
Redwood Wealth Management Group
Medford,
New Jersey
|
+$7.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$216K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$71.1K |
| 3 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$59.3K |
| 4 |
PA
Parallel Advisors
San Francisco,
California
|
-$4.57K |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$394 |
CLGN Hedge Fund Activity: Q2 2024 in Review
16 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q2 2024, worth a combined $7.39M — down 2.6% from $7.59M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLGN positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was AMH Equity, opening a new position worth an estimated $420K. The largest seller was Roumell Asset Management, cutting an estimated $216K.
- 16 institutional investors held CollPlant Biotechnologies (CLGN) as of Q2 2024, up from 13 in Q1 2024.
- Funds reported $7.39M of CollPlant Biotechnologies stock for Q2 2024, down 2.6% quarter-over-quarter.
- 4 funds opened new CollPlant Biotechnologies positions in Q2 2024 and 1 closed out, a net change of +3 holders.
- The largest CollPlant Biotechnologies buyer in Q2 2024 was AMH Equity, an estimated $420K added.
- The largest CollPlant Biotechnologies seller in Q2 2024 was Roumell Asset Management, an estimated $216K sold.
Based on aggregated 13F filings for Q2 2024.